Modeling interaction of Glioma cells and CAR T-cells considering multiple CAR T-cells bindings
Chimeric antigen receptor (CAR) T-cell based immunotherapy has shown its potential in treating blood cancers, and its application to solid tumors is currently being extensively investigated. For glioma brain tumors, various CAR T-cell targets include IL13Ra2, EGFRvIII, HER2, EphA2, GD2, B7-H3, and c...
Saved in:
Published in | arXiv.org |
---|---|
Main Authors | , , , , , , |
Format | Paper |
Language | English |
Published |
Ithaca
Cornell University Library, arXiv.org
18.01.2022
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Chimeric antigen receptor (CAR) T-cell based immunotherapy has shown its potential in treating blood cancers, and its application to solid tumors is currently being extensively investigated. For glioma brain tumors, various CAR T-cell targets include IL13Ra2, EGFRvIII, HER2, EphA2, GD2, B7-H3, and chlorotoxin. In this work, we are interested in developing a mathematical model of IL13Ra2 targeting CAR T-cells for treating glioma. We focus on extending the work of Kuznetsov et al. (1994) by considering binding of multiple CAR T-cells to a single glioma cell, and the dynamics of these multi-cellular conjugates. Our model more accurately describes experimentally observed CAR T-cell killing assay data than a model which does not consider cell binding. Moreover, we derive conditions in the CAR T-cell expansion rate that determines treatment success or failure. Finally, we show that our model captures distinct CAR T-cell killing dynamics at low, medium, and high antigen receptor densities in patient-derived brain tumor cells. |
---|---|
ISSN: | 2331-8422 |